AriBio to Present AR1001 Phase 3 Data at CTAD

The Boston conference opens November 16 with results from a global trial of an oral Alzheimer's drug candidate.

Updated on Nov. 11, 2026 in Alzheimer’s

Bold vector editorial illustration of a single smooth oval capsule on pale blue crystalline granules, with a faint neuron shadow behind it.
AriBio will present 52-week phase 3 results for its oral Alzheimer's candidate AR1001, tested in 1,535 patients, at a Boston conference opening November 16. AI Illustration. Upload story photo >

Live Poll

Would you trust a new oral Alzheimer's drug if trials showed it slowed memory loss?

AriBio will present results from its global phase 3 POLARIS-AD trial of AR1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference, opening November 16 in Boston. The trial enrolled 1,535 patients with early Alzheimer's disease who received either AR1001 or a placebo for 52 weeks.

Why it matters

Alzheimer's accounts for 60-70% of all dementia cases, and the conference is expected to highlight a shift in drug development from amyloid removal toward diverse therapeutic pathways. The outcome will show whether AR1001, an oral once-daily candidate, can statistically slow cognitive decline compared with placebo.

The phase 3 POLARIS-AD trial enrolled 1,535 patients and compared AR1001 against placebo over 52 weeks, with assessments of cognitive function and daily living abilities. Efficacy and safety results, including a 52-week extension study, will be disclosed at CTAD 2026.

The players

AriBio

AriBio is a South Korean biopharmaceutical company developing AR1001 for Alzheimer's disease.

Roche

Roche is a Swiss pharmaceutical company whose trontinemab analyses are also being presented at CTAD 2026.

The details

AR1001 is an oral Alzheimer's drug candidate taken once daily that inhibits PDE5, an enzyme involved in neuronal signaling in the brain. The presentation will also include safety results from an extension study, alongside related analyses at the same conference.

Timeline

  1. November 16, 2026: CTAD 2026 opens with AriBio's AR1001 phase 3 presentation in Boston.

  2. November 16–19, 2026: The 19th CTAD conference is held in Boston.

  3. Annually since 2008: CTAD has been held each year.

Health Landscape

Leqembi has been approved for three years and removes amyloid-beta to slow cognitive decline in early-stage patients, but carries risks of brain swelling or bleeding. AR1001 and Roche's trontinemab, which uses its proprietary 'Brain Shuttle' technology to cross the blood-brain barrier, reflect the broader pursuit of therapies beyond amyloid removal.

AR1001 is taken as a daily oral pill rather than through infusion, which would matter to patients and caregivers if the trial shows benefit. Whether it becomes available depends on the trial results, regulatory review, and cost, none of which have been determined yet.

The takeaway

Alzheimer's drug development is moving beyond amyloid removal, and the AR1001 results will show whether an oral, non-amyloid option can meaningfully slow cognitive decline. Readers should watch for the statistical outcome against placebo before drawing conclusions about its clinical value.

What happens next

AriBio's AR1001 phase 3 results are scheduled for presentation at CTAD 2026 on November 16, 2026, in Boston.

Further reading

Explore more on Alzheimer’s research and treatment developments.

Source note: This article includes information reported by 조선일보.

Live Poll

Would you trust a new oral Alzheimer's drug if trials showed it slowed memory loss?